CLASS II Drug recall · Reported 3 Sep 2014 · FDA Enforcement Report

Glycopyrrolate 0.2 mg/ml pre-filled syringe recalled

Pharmakon Pharmaceuticals is recalling Glycopyrrolate 0.2 mg/ml pre-filled syringe, distributed in Illinois, Indiana, Maryland, Texas. The recall was initiated on 21 Apr 2014 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: E131210.212 Exp: 07/14/2014
Quantity recalled200 Syringes

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1567-2014
FDA event ID
68191
Recalling firm
Pharmakon Pharmaceuticals, Noblesville, IN
Classification
Class II
Status
Terminated
Recall initiated
21 Apr 2014
FDA classified
26 Aug 2014
Reported
3 Sep 2014
Type
Voluntary: Firm initiated
Customers notified by
Telephone
Reason category
Labeling Errors

Timeline

21 Apr 2014Recall initiated by company
26 Aug 2014Classified by FDA+127 days
3 Sep 2014Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Incorrect/ Undeclared Excipient: Contains undeclared benzyl alcohol.

Product as listed by the FDA

Glycopyrrolate 0.2 mg/ml, 5 mL pre-filled syringe, Rx Only. Pharmakon Pharmaceuticals, Inc., 14450 Getz Rd., Noblesville, IN 46060, NDC#: 45183-0965-70.

Where it was distributed

United States: TX, IL, MD, IN

IllinoisIndianaMarylandTexas

Questions about this recall

Why was it recalled?

Incorrect/ Undeclared Excipient: Contains undeclared benzyl alcohol.

Which lots are affected?

Lot #: E131210.212 Exp: 07/14/2014

Where was it sold?

United States: TX, IL, MD, IN

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

3 other products · FDA event 68191

More recalls from Pharmakon Pharmaceuticals

All 116

Other Glycopyrrolate recalls

All 43